MOH vs. HUM, CNC, BNTX, BAX, STE, ARGX, ILMN, PHG, ALGN, and GMAB
Should you be buying Molina Healthcare stock or one of its competitors? The main competitors of Molina Healthcare include Humana (HUM), Centene (CNC), BioNTech (BNTX), Baxter International (BAX), STERIS (STE), argenx (ARGX), Illumina (ILMN), Koninklijke Philips (PHG), Align Technology (ALGN), and Genmab A/S (GMAB). These companies are all part of the "medical" sector.
Humana (NYSE:HUM) and Molina Healthcare (NYSE:MOH) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.
Humana received 357 more outperform votes than Molina Healthcare when rated by MarketBeat users. Likewise, 64.12% of users gave Humana an outperform vote while only 57.05% of users gave Molina Healthcare an outperform vote.
In the previous week, Humana had 31 more articles in the media than Molina Healthcare. MarketBeat recorded 51 mentions for Humana and 20 mentions for Molina Healthcare. Humana's average media sentiment score of 0.74 beat Molina Healthcare's score of 0.48 indicating that Molina Healthcare is being referred to more favorably in the news media.
Humana has higher revenue and earnings than Molina Healthcare. Humana is trading at a lower price-to-earnings ratio than Molina Healthcare, indicating that it is currently the more affordable of the two stocks.
92.4% of Humana shares are held by institutional investors. Comparatively, 98.5% of Molina Healthcare shares are held by institutional investors. 0.3% of Humana shares are held by insiders. Comparatively, 1.1% of Molina Healthcare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Humana presently has a consensus price target of $437.00, suggesting a potential upside of 40.54%. Molina Healthcare has a consensus price target of $393.09, suggesting a potential upside of 6.47%. Given Molina Healthcare's stronger consensus rating and higher possible upside, equities analysts plainly believe Humana is more favorable than Molina Healthcare.
Molina Healthcare has a net margin of 3.20% compared to Molina Healthcare's net margin of 2.34%. Humana's return on equity of 32.34% beat Molina Healthcare's return on equity.
Humana has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, Molina Healthcare has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.
Summary
Humana and Molina Healthcare tied by winning 9 of the 18 factors compared between the two stocks.
Get Molina Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for MOH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MOH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Molina Healthcare Competitors List
Related Companies and Tools
